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Reply
Response to ‘‘Validating discovery in literature-based
discovery’’
Dr. Kostoﬀ’s letter illustrates how challenging it is to
evaluate discovery systems, such as the LitLinker system
in the paper that he critiqued. It is diﬃcult to predict the fu-
ture, and it is perhaps even more diﬃcult to determine
whether a system can predict the future accurately. In our
critiqued paper, we attempted to accomplish both diﬃcult
tasks—using LitLinker to predict disease–chemical correla-
tions that would hold in the future, and evaluatingwhether it
could predict the future accurately. Our paper is one of the
few papers that presents results from a quantitative evalua-
tion of a literature-based discovery system because no one
has devised a perfect way to perform such evaluations.
One key question is particularly diﬃcult to answer: when
is something ‘‘known’’? In this particular situation, we need
to knowwhen a correlation between a disease and some sub-
stance becomes ‘‘known’’, and thus is a candidate for discov-
ery if a discovery system is run on material before that time.
Is something known when someone suggests that there
could be a connection? Is it when several researchers believe
that there is a connection? Is it whenmost researchers believe
that there is a connection? Is it when knowledge of this con-
nection aﬀects clinical practice? Using the best level of evi-
dence from a medical professional’s standpoint, a
perceived correlation is a trusted one that should aﬀect clin-
ical practice if it holds in a meta-analysis of multiple, large-
scale, well-designed randomized controlled trials [1]. If we
require that level of evidence, then none of our ‘‘discoveries’’
are trustworthy even today, and they certainly were not be-
fore January of 2004, the end point for the run of LitLinker.
The appropriate deﬁnition of ‘‘known’’ for these discovery
systems is probably somewhere between the two extremes.
Thus, a main issue for any discovery system is where to
draw the known vs. unknown line or where to set the dis-
covery threshold. In our paper, we chose to deﬁne a known
correlation as any correlation that occurs at least once
among the MeSH terms in the MEDLINE literature. As
Dr. Kostoﬀ points out, we could have been even more con-
servative in deﬁning a discovery threshold.
Let’s look at each of the three discovery cases that he
critiques in detail. His ﬁrst example is of the correlation
between endocannibinoids and Alzheimer’s disease. As
we stated in our article, no documents in MEDLINE
before 2004 contain both MeSH terms [2]. However, as
Dr. Kostoﬀ pointed out, a search for those terms in the ab-
stract does yield three papers [3–5]. In these documents,
Neuroprotective Agents was the only MeSH term that
appeared to link the correlations. In contrast, LitLinker sug-
gested nine terms to link endocannibinoids and Alzheimer’s
disease that could provide a fruitful direction for research.
Three of those linking terms were used in the example we
gave to illustrate LitLinker’s discovery [6]. The other docu-
ment that Dr. Kostoﬀ refers to does not mention Alzhei-
mer’s disease in the MEDLINE record [7]; thus, it would
be diﬃcult for any automated process to identify.
For the second example of AMPA receptors and Mi-
graine, a search in MEDLINE before 2004 using the corre-
sponding MeSH terms yields no papers. In the list of
papers that Dr. Kostoﬀ cites as evidence that this correla-
tion was known prior to 2004, one is not in MEDLINE
[8], and one does not contain either AMPA or LY293558
in the abstract [9]. Thus, it is diﬃcult to see how an auto-
mated search could ﬁnd those papers.
For the third example of secretin and Schizophrenia,
there were no papers published in MEDLINE before
2004 with the corresponding MeSH terms, nor were there
any that included the terms or any of their synonyms in
the abstract or title. The only example that Dr. Kostoﬀ
provided was a patent. Given the poor accessibility, lim-
ited peer review, and prevalence of provisional patents,
we see no need to require a patent search in addition
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to a MEDLINE search before determining whether a
correlation is known.
Dr. Kostoﬀ’s caution about over reliance on manually
assigned index terms such as MeSH is well taken, and we
have a manuscript in preparation that reports on a com-
parison of LitLinker’s performance using MeSH terms to
natural language processing that extracts medical terms
from the abstract. However, natural language processing
of MEDLINE abstracts takes at least an order of magni-
tude longer to process than MeSH terms, and can suﬀer
from similar types of indexing problems [10].
Another important factor to consider is that we are trying
to perform a quantitative, automatic evaluation because
fast, repeatable evaluation methodologies are needed to
compare systems and thus promote further enhancement
of these systems. Since the publication of that paper, we have
worked to further advance evaluationmethodologies for this
ﬁeld through our book chapter on evaluation [11] and in a
paper in preparation that proposes an even more thorough
quantitative evaluation methodology. Much of what
Dr. Kostoﬀ listed as evidence that LitLinker’s discovered
correlations were already known requires a large amount
of manual eﬀort, and thus would not lend itself well to an
automated evaluation methodology.
The ultimate question for a discovery system is: does it
help researchers in the discovery process? Unfortunately,
such a question is diﬃcult to answer easily, automatically,
quantitatively, or on a large scale, all of which are necessary
criteria for an evaluation methodology that will help infor-
maticists improve the algorithms behind these discovery sys-
tems. The evaluation methodology that we used and that we
continue to enhance is automatic, quantitative, and scalable.
Is our evaluationmethodologyperfect?Certainly not, butwe
maintain that it serves a useful purpose in helping informati-
cists assess and improve literature-based discovery systems.
We have always envisioned LitLinker as an interactive
tool that researchers use to explore possible new research
directions from the literature [12], and we believe tools such
as LitLinker will prove useful, even with our current dis-
covery threshold. Alternatively, LitLinker could be en-
hanced to let the researcher have control over the
discovery threshold. The researcher is the best judge of
where that threshold should be and could desire diﬀerent
thresholds for diﬀerent situations. Such user control is cen-
tral to our design philosophy for LitLinker.
If we continue with automated, quantitative evaluations
and require an extremely conservative discovery threshold
as Dr. Kostoﬀ expects, it may well lead us to overlook dis-
coveries that could be fostered in the near term (i.e., those
discoveries most likely to be pursued). For example, the
most famous, and well-respected examples of literature-
based discovery, do not meet Dr. Kostoﬀ’s conservative
criteria for a discovery. For four of Swanson’s six discover-
ies from the literature, at least one publication contains
both terms in the discovered correlations prior to each of
Swanson’s four published discoveries [13–16]. Nonetheless,
Swanson’s discoveries did foster biomedical research on
those correlations as well as fuel further development on
literature-based discovery systems. Thus, we view Swan-
son’s discoveries as excellent examples of success.
All these examples point to the key motivation behind
literature-based discovery systems—the volume of biomed-
ical and related information is so extreme that researchers
cannot keep up with it and use it eﬀectively or eﬃciently.
The advantage of these literature-based discovery tools is
that they sift through a huge information space to suggest
future research directions and provide connections to the
literature that support those directions. We hope that this
exchange between Dr. Kostoﬀ and ourselves will serve to
further encourage, rather than discourage, the much
needed system evaluations as well as new evaluation meth-
odologies that will guide future development of these
important literature-based discovery systems.
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